AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31

20/20 Biolabs, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.26−0.00 (-0.12%)

Close on Oct 19, 2026

Market cap: $2.81M
P/E (TTM): –
Dividend yield: –

20/20 Biolabs, Inc. cash flow statement

Annual QuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31
Depreciation & Amortization	0.06	0.12
Stock-Based Compensation	0.52	2.18
Change in Accounts Receivable	-0.06	-0.07
Change in Inventory	-0.07	0.01
Change in Accounts Payable	0.50	0.01
Change in Unearned Revenue	-0.06	0.27
Operating Cash Flow	-1.92	-2.60
Financing Cash Flow	1.16	0.29
Net Change in Cash	-0.76	-2.31

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: 29.6%
Operating margin: -162.9%
Net margin: -182.8%
Return on equity, FY2025: -503.1%

Financial strength

Current ratio: 1.99
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 178.2%

Valuation

P/E ratio: –
Price to sales: 1.37
Price to book: 1.73
Dividend yield: –